The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Microalbumin Random Urine with Creatinine
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Insulin (fasting)
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
The DH-3. Diabetes Health panel contains 7 tests with 66 biomarkers.
Brief Description: The DH-3 Diabetes Health panel is a comprehensive diagnostic panel designed for an in-depth analysis of diabetes management and its impact on overall health. It includes a series of tests: C-Reactive Protein (CRP), CBC with Differential and Platelets, Comprehensive Metabolic Panel (CMP), Hemoglobin A1c, Insulin, Lipid Panel, and Random Urine Microalbumin with Creatinine. This panel not only assesses blood sugar control and diabetes management but also evaluates cardiovascular risk, kidney function, and the body's insulin production and response.
Collection Method: Blood Draw and Urine Collection
Specimen Type: Whole Blood, Serum, and Urine
Test Preparation: Patient should be fasting for at least 9 hours prior to collection.
The DH-3 panel is typically ordered for individuals with diabetes who require a detailed assessment of their condition, particularly if there are concerns about complications or if standard management strategies are not achieving desired outcomes. It's also used for patients showing signs of insulin resistance or cardiovascular risk factors, providing critical information to tailor treatment plans more effectively.
C-Reactive Protein (CRP): Measures the level of CRP in the blood, an indicator of inflammation. High levels are associated with an increased risk of cardiovascular disease, which is particularly relevant for individuals with diabetes.
CBC with Differential and Platelets: Provides a comprehensive overview of the blood cells, including red blood cells, white blood cells, and platelets, helping to identify conditions such as anemia or infections that could complicate diabetes management.
Comprehensive Metabolic Panel (CMP): Offers insights into glucose levels, kidney and liver function, electrolyte and fluid balance, and blood proteins, essential for monitoring the metabolic effects of diabetes.
Hemoglobin A1c: Gives an average of blood glucose levels over the past two to three months, indicating how well diabetes is being controlled.
Insulin: Measures the level of insulin in the blood, providing information on how the body is producing and using insulin, which is crucial for understanding insulin resistance and diabetes management.
Lipid Panel: Assesses the levels of cholesterol and triglycerides, important for evaluating cardiovascular risk in diabetic patients.
Random Urine Microalbumin with Creatinine: Detects early signs of kidney damage by measuring albumin in the urine, a common issue in diabetes management.
While the DH-3 Diabetes Health panel offers a thorough evaluation of diabetes and its broader health impacts, the DH-4 Diabetes Health panel takes this a step further. It includes all tests from DH-3 and adds a 2 Specimen Glucose Tolerance Test and a 2 Specimen Insulin Response to Glucose. These additional tests provide an in-depth look at how the body processes glucose and responds to insulin over time, making it invaluable for diagnosing different types of diabetes, assessing insulin resistance more precisely, and fine-tuning treatment approaches for optimal control.
The DH-3 panel is instrumental in managing diabetes and identifying potential complications. It checks for insulin resistance, cardiovascular risks (through CRP and the Lipid Panel), early kidney damage (via urine microalbumin), and the effectiveness of diabetes management strategies (through HbA1c and CMP). It also helps in detecting other conditions that may affect diabetes management, like liver disease and infections.
Healthcare professionals leverage the DH-3 panel results to adjust diabetes management plans, addressing insulin resistance, modifying cardiovascular risk factors, and managing early kidney damage. High CRP levels might lead to interventions aimed at reducing cardiovascular risk, while adjustments in insulin therapy could be guided by the insulin and HbA1c results. Abnormal findings in the urine microalbumin test might prompt early interventions to preserve kidney function.
The DH-3 Diabetes Health panel stands as a critical resource for those managing diabetes, providing a comprehensive overview that extends beyond glucose control to include cardiovascular health, kidney function, and insulin dynamics. By offering detailed insights into the interplay between diabetes and various health parameters, this panel supports healthcare professionals in crafting nuanced, effective management plans, ultimately enhancing the quality of life for individuals with diabetes.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.